92 related articles for article (PubMed ID: 20415057)
1. Detection of short-term chromosomal damage due to therapeutic 131I exposure in patients with thyroid cancer.
Hernández-Jardines A; Molina B; del Castillo V; Papadakis M; Rivera T; Azorín J; Herrera LA; Yokoyama E; Frías S
Rev Invest Clin; 2010; 62(1):31-8. PubMed ID: 20415057
[TBL] [Abstract][Full Text] [Related]
2. Cytokinesis-block micronucleus test in patients undergoing radioiodine therapy for differentiated thyroid carcinoma.
Popova L; Hadjidekova V; Hadjieva T; Agova S; Vasilev I
Hell J Nucl Med; 2005; 8(1):54-7. PubMed ID: 15886755
[TBL] [Abstract][Full Text] [Related]
3. Chromosome aberrations after treatment with radioactive iodine for thyroid cancer.
Baugnet-Mahieu L; Lemaire M; Léonard ED; Léonard A; Gerber GB
Radiat Res; 1994 Dec; 140(3):429-31. PubMed ID: 7972697
[TBL] [Abstract][Full Text] [Related]
4. The radiotoxicity of 131I therapy of thyroid cancer: assessment by micronucleus assay of B lymphocytes.
Watanabe N; Kanegane H; Kinuya S; Shuke N; Yokoyama K; Kato H; Tomizawa G; Shimizu M; Funada H; Seto H
J Nucl Med; 2004 Apr; 45(4):608-11. PubMed ID: 15073256
[TBL] [Abstract][Full Text] [Related]
5. Radiotoxicity after iodine-131 therapy for thyroid cancer using the micronucleus assay.
Watanabe N; Yokoyama K; Kinuya S; Shuke N; Shimizu M; Futatsuya R; Michigishi T; Tonami N; Seto H; Goodwin DA
J Nucl Med; 1998 Mar; 39(3):436-40. PubMed ID: 9529288
[TBL] [Abstract][Full Text] [Related]
6. Biologic dosimetry in thyroid cancer patients after repeated treatments with iodine-131.
M'Kacher R; Schlumberger M; Légal JD; Violot D; Béron-Gaillard N; Gaussen A; Parmentier C
J Nucl Med; 1998 May; 39(5):825-9. PubMed ID: 9591584
[TBL] [Abstract][Full Text] [Related]
7. Empiric radioactive iodine dosing regimens frequently exceed maximum tolerated activity levels in elderly patients with thyroid cancer.
Tuttle RM; Leboeuf R; Robbins RJ; Qualey R; Pentlow K; Larson SM; Chan CY
J Nucl Med; 2006 Oct; 47(10):1587-91. PubMed ID: 17015892
[TBL] [Abstract][Full Text] [Related]
8. [Cytogenetic study of thyroid patients treated with external irradiation or radioiodine].
Katz N; Esik O; Füzy M; Gundy S
Orv Hetil; 1998 Jun; 139(25):1521-6. PubMed ID: 9676113
[TBL] [Abstract][Full Text] [Related]
9. Micronuclei frequency in peripheral blood lymphocytes of thyroid cancer patients after radioiodine therapy and its relationship with metastasis.
Joseph LJ; Bhartiya US; Raut YS; Kand P; Hawaldar RW; Nair N
Mutat Res; 2009 Apr; 675(1-2):35-40. PubMed ID: 19386245
[TBL] [Abstract][Full Text] [Related]
10. The success of 131I ablation in thyroid cancer patients is significantly reduced after a diagnostic activity of 40 MBq 131I.
Verburg FA; Verkooijen RB; Stokkel MP; van Isselt JW
Nuklearmedizin; 2009; 48(4):138-42; quiz N19-20. PubMed ID: 19384451
[TBL] [Abstract][Full Text] [Related]
11. Multicolour FISH detection of radioactive iodine-induced 17cen-p53 chromosomal breakage in buccal cells from therapeutically exposed patients.
Ramírez MJ; Puerto S; Galofré P; Parry EM; Parry JM; Creus A; Marcos R; Surrallés J
Carcinogenesis; 2000 Aug; 21(8):1581-6. PubMed ID: 10910962
[TBL] [Abstract][Full Text] [Related]
12. Effect of in vivo exposure to iodine-131 on the frequency and persistence of micronuclei in human lymphocytes.
Livingston GK; Foster AE; Elson HR
J Toxicol Environ Health; 1993; 40(2-3):367-75. PubMed ID: 8230307
[TBL] [Abstract][Full Text] [Related]
13. Analysis of cell kinetics, chromosome aberration frequency and sister chromatid exchanges in lymphocyte "in vitro" cultures of patients irradiated by 131I. Preliminary note.
Ardito G; Lamberti L; Cottino F; Piccotti F
Boll Soc Ital Biol Sper; 1983 Jan; 59(2):135-41. PubMed ID: 6860485
[TBL] [Abstract][Full Text] [Related]
14. Cumulative doses of adjunct 131I treatment depend on location of residual thyroid tissue after total thyroidectomy in differentiated thyroid cancer.
Saint-Vil D; Emran MA; Lambert R; Alos N; Turpin S; Huot C
J Pediatr Surg; 2007 May; 42(5):853-6. PubMed ID: 17502198
[TBL] [Abstract][Full Text] [Related]
15. Blood dosimetry and dose-rate effects after radioiodine therapy of differentiated thyroid cancer.
Lassmann M; Luster M; Hänscheid H; Reiners C
J Nucl Med; 2005 May; 46(5):899. PubMed ID: 15872368
[No Abstract] [Full Text] [Related]
16. Biological dosimetry in patients treated with iodine-131 for differentiated thyroid carcinoma.
M'Kacher R; Legal JD; Schlumberger M; Voisin P; Aubert B; Gaillard N; Parmentier C
J Nucl Med; 1996 Nov; 37(11):1860-4. PubMed ID: 8917193
[TBL] [Abstract][Full Text] [Related]
17. Factors affecting 131I-Lym-1 pharmacokinetics and radiation dosimetry in patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
DeNardo GL; DeNardo SJ; Shen S; DeNardo DA; Mirick GR; Macey DJ; Lamborn KR
J Nucl Med; 1999 Aug; 40(8):1317-26. PubMed ID: 10450684
[TBL] [Abstract][Full Text] [Related]
18. Adjuvant external-beam radiotherapy in patients with high-risk well-differentiated thyroid cancer.
Chen PV; Osborne R; Ahn E; Avitia S; Juillard G
Ear Nose Throat J; 2009 Jul; 88(7):E01. PubMed ID: 19623515
[TBL] [Abstract][Full Text] [Related]
19. Sequential biological dosimetry after a single treatment with iodine-131 for differentiated thyroid carcinoma.
M'Kacher R; Légal JD; Schlumberger M; Aubert B; Beron-Gaillard N; Gaussen A; Parmentier C
J Nucl Med; 1997 Mar; 38(3):377-80. PubMed ID: 9074522
[TBL] [Abstract][Full Text] [Related]
20. Patient parameters and other radiation safety issues in 131I therapy for thyroid cancer treatment.
Al-Haj AN; Lagarde CS; Lobriguito AM
Health Phys; 2007 Dec; 93(6):656-66. PubMed ID: 17993846
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]